Abstract 4619: Epigenetic therapy and sensitization of lung cancer to immunotherapy.
John Wrangle(Johns Hopkins University), Stephen B. Baylin(Johns Hopkins University), Julie R. Brahmer(Johns Hopkins University), Xiaoyu Pan(Peking University), Frank P. Vendetti(University of Pittsburgh), Hariharan Easwaran(Johns Hopkins University), Janis M. Taube(Bloomberg (United States)), Charles M. Rudin(Memorial Sloan Kettering Cancer Center), Suzanne L. Topalian(Bloomberg (United States)), Cynthia A. Zahnow(Johns Hopkins University), Drew M. Pardoll(Bloomberg (United States)), Kirsten Harbom(Johns Hopkins Hospital), Princy Parsana(Johns Hopkins University), Peter A. Jones(Van Andel Institute), Wei Wang(Fujian Normal University), Malcolm V. Brock(Johns Hopkins University), Alexander Koch(Ghent University), Helai P. Mohammad(Arysta LifeScience (France)), Kristen Rodgers(Johns Hopkins University)
Cited by 1
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k